5-苯基-1,3-二氢苯并咪唑-2-酮 | 100381-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 5-苯基-1,3-二氢苯并咪唑-2-酮
• 英文名称: 5-phenyl-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 5-phenyl-1,3-dihydro-benzimidazol-2-one；5-Phenyl-1,3-dihydro-benzimidazol-2-on；5-Phenyl-1H-benzoimidazol-2-ol；5-phenyl-1,3-dihydrobenzimidazol-2-one
• CAS: 100381-95-1
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: HMJMLMGHUONOEL-UHFFFAOYSA-N

物化性质

• 熔点：
  350 °C(Solv: acetic acid (64-19-7))
• 沸点：
  282.2±10.0 °C(Predicted)
• 密度：
  1.219±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-苯基-1,3-二氢苯并咪唑-2-酮 在 一水合肼 、 三氯氧磷 作用下， 以 溶剂黄146 为溶剂， 反应 3.5h， 生成
  参考文献：
  名称：

  Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs

  摘要：

  A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H- pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.008
• 作为产物：
  描述：

  4-溴邻苯二胺 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 5.0h， 生成 5-苯基-1,3-二氢苯并咪唑-2-酮
  参考文献：
  名称：

  [EN] TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE
  [FR] DÉRIVÉS DE TRIAZOLONES POUR UTILISATION DANS LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION D'UNE MALADIE VIRALE

  摘要：

  本发明涉及具有一般式（I）的化合物，可选地以药用可接受的盐、溶剂合物、多晶形态、前药、互变异构体、拉克米特、共药、共晶、对映体或二对映体或其混合物的形式存在，该化合物在治疗、缓解或预防病毒性疾病方面具有用途。此外，还披露了具体的联合疗法。

  公开号：

  WO2017046318A1

文献信息

• Synthesis of Some Substituted Benzoxazolones
  作者：Robert L. Clark、Arsenio A. Pessolano

  DOI：10.1021/ja01540a038

  日期：1958.4
• Design, syntheses, and structure–activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4′-piperidin]-1′-yl}benzimidazole derivatives
  作者：Yoshio Ogino、Norikazu Ohtake、Yoshikazu Nagae、Kenji Matsuda、Minoru Moriya、Takuya Suga、Makoto Ishikawa、Maki Kanesaka、Yuko Mitobe、Junko Ito、Tetsuya Kanno、Akane Ishihara、Hisashi Iwaasa、Tomoyuki Ohe、Akio Kanatani、Takehiro Fukami

  DOI：10.1016/j.bmcl.2008.08.018

  日期：2008.9

  Design, syntheses, and structure-activity relationships of a novel class of 2-3-oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole NPY Y5 receptor antagonists are described. The benzimidazole structures were newly designed based on the urea linkage of our prototype Y5 receptor antagonists (2 and 3). By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k). Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
• Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
  申请人：F. Hoffmann-La Roche AG

  公开号：US20170081323A1

  公开（公告）日：2017-03-23

  The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
• Design and synthesis of prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors as anti-prostate cancer drugs
  作者：Syuhei Nakao、Miyuki Mabuchi、Tadashi Shimizu、Yoshihiro Itoh、Yuko Takeuchi、Masahiro Ueda、Hiroaki Mizuno、Naoko Shigi、Ikumi Ohshio、Kentaro Jinguji、Yuko Ueda、Masatatsu Yamamoto、Tatsuhiko Furukawa、Shunji Aoki、Kazutake Tsujikawa、Akito Tanaka

  DOI：10.1016/j.bmcl.2014.01.008

  日期：2014.2

  A series of 1-aryl-3,4-substituted-1H-pyrazol-5-ol derivatives was synthesized and evaluated as prostate cancer antigen-1 (PCA-1/ALKBH3) inhibitors to obtain a novel anti-prostate cancer drug. After modifying 1-(1H-benzimidazol-2-yl)-3,4-dimethyl-1H-pyrazol-5-ol (1), a hit compound found during random screening using a recombinant PCA-1/ALKBH3, 1-(1H-5-methylbenzimidazol-2-yl)-4-benzyl-3-methyl-1H- pyrazol-5-ol (35, HUHS015), was obtained as a potent PCA-1/ALKBH3 inhibitor both in vitro and in vivo. The bioavailability (BA) of 35 was 7.2% in rats after oral administration. As expected, continuously administering 35 significantly suppressed the growth of DU145 cells, which are human hormone-independent prostate cancer cells, in a mouse xenograft model without untoward effects. (C) 2014 Elsevier Ltd. All rights reserved.
• [EN] TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE<br/>[FR] DÉRIVÉS DE TRIAZOLONES POUR UTILISATION DANS LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION D'UNE MALADIE VIRALE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017046318A1

  公开（公告）日：2017-03-23

  The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

  本发明涉及具有一般式（I）的化合物，可选地以药用可接受的盐、溶剂合物、多晶形态、前药、互变异构体、拉克米特、共药、共晶、对映体或二对映体或其混合物的形式存在，该化合物在治疗、缓解或预防病毒性疾病方面具有用途。此外，还披露了具体的联合疗法。